File: Attachment 2026-07-13 AGSM FINAL.pdf

NetraMark Reports Its Annual General And Special Meeting Results

TORONTO, ON, July 13, 2026 NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), is pleased to announce that the successful Annual General and Special Meeting of shareholders was held on July 13, 2026. A total of 42,813,285 common shares (approximately 47.59% of the outstanding common shares) were represented in person or proxy.

1. NUMBER OF DIRECTORS

Resolution to set the number of directors of the Company for the ensuing year at four (4) persons was passed by 99.93% For and 4.064% Against.

2. ELECTION OF DIRECTORS

Each of the following individuals were elected as directors of the Company as approved by a vote by ballot, for a term expiring at the conclusion of the next annual meeting of shareholders of the Company or until their successors are elected or appointed, as follows:

Name Votes "For" (%) Votes "Withheld" (%) GEORGE ACHILLEOS 99.886% 0.114% PATRICK JOSEPH HALEY 99.988% 0.012% JOSEPH GERACI 99.729% 0.271% ANDREW PARKS 95.233% 0.4.767%

3. APPOINTMENT OF AUDITOR

The appointment of Horizon Assurance LLP , Chartered Professional Accountants, as the auditor of the Company, to hold office until the next annual meeting of shareholders of the Company, and the authorization of the directors of the Company to fix the auditor's remuneration, was approved by a resolution passed by a vote by ballot, with 44,806,875 (99.984%) total votes cast For and 6,410 (0.016%) Withheld.

4. APPROVAL 2026 ROLLING STOCK OPTION PLAN

Resolution to approve the 2026 Rolling Stock Option Plan passed by a vote by ballot, with 44,412,430 (99.727%) total votes cast For and 121,465 (0.273%) Against.

5. APPROVAL OF THE 2026 EQUITY INCENTIVE PLAN

Resolution to approve the 2026 Equity Incentive Plan passed by a vote by ballot, with 44,412,430 (99.727%) total votes cast For and 121,465 (0.273%) Against.

About NetraMark

1 of 2 NetraMark is focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are targeted at the biotechnology and pharmaceutical industries. The Company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets often prevalent in clinical trials, and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this news release. The information contained in this news release was accurate at the time of dissemination but may be superseded by subsequent news release(s). The Company is under no obligation, nor does it intend to update or revise the forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

Contact Information: Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549 Adam Peeler Investor Relations | adam.peeler@loderockadvisors.com | 416-427-1235 LodeRock Advisors 1 Toronto St, Suite 202 Toronto, Ontario M5C 2W4

2